Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,060 | 2,440 | 07.09. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.08. | Monogram Technologies Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.08. | Monogram Technologies Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.08. | Monogram Technologies Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
14.08. | Monogram Technologies Inc.: Monogram Technologies Reports Second Quarter 2024 Financial Results | 242 | ACCESSWIRE | Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA SystemSecured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby LimitedManagement to Host... ► Artikel lesen | |
12.08. | Monogram Technologies announces strategic collaboration with Shalby Limited | 2 | Seeking Alpha | ||
12.08. | Monogram Technologies Inc.: Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration | 235 | ACCESSWIRE | Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mB?s TKA SystemStrategic Partner Shalby is Recognized as... ► Artikel lesen | |
08.08. | Monogram Technologies seeks FDA clearance for surgery robot | 2 | Investing.com | ||
08.08. | Monogram Technologies Inc.: Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance | 350 | ACCESSWIRE | Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive ReviewFDA Decision is Expected Within 90 Days of Initial Submission; However, the Process... ► Artikel lesen | |
08.08. | Monogram Technologies Inc. - 8-K, Current Report | 2 | SEC Filings | ||
01.08. | Monogram Technologies Inc.: Monogram Technologies to Host Second Quarter 2024 Business Update Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time | 255 | ACCESSWIRE | AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus... ► Artikel lesen | |
22.07. | Monogram Technologies Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.07. | Monogram Technologies Inc. - 8-K, Current Report | 1 | SEC Filings | ||
03.06. | Monogram Technologies Inc.: Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June 20th, 2024 | 217 | ACCESSWIRE | Management to Showcase Product Demonstration of mBôs Precision Robotic Surgical System and mVision Technologies AUSTIN, TX / ACCESSWIRE / June 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram"... ► Artikel lesen | |
15.05. | Monogram Orthopaedics reports Q1 results | 1 | Seeking Alpha | ||
15.05. | Monogram Orthopaedics Inc.: Monogram Orthopaedics Completes Corporate Name Change to Monogram Technologies | 593 | ACCESSWIRE | New Name Reflects Continued Evolution as an AI-Driven Robotics Company with a Strong IP Position AUSTIN, TX / ACCESSWIRE / May 15, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the... ► Artikel lesen | |
14.05. | MONOGRAM ORTHOPAEDICS INC: Monogram Orthopaedics Reports First Quarter 2024 Financial Results | 324 | ACCESSWIRE | Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half of 2024Engaged Contract Research Organization to Oversee mBôs Robot... ► Artikel lesen | |
14.05. | MONOGRAM ORTHOPAEDICS INC - 8-K, Current Report | 2 | SEC Filings | ||
14.05. | MONOGRAM ORTHOPAEDICS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.05. | MONOGRAM ORTHOPAEDICS INC: Monogram Engages Contract Research Organization to Oversee mBôs Robot Clinical Trial Activities Outside the U.S. | 630 | ACCESSWIRE | CRO Expands Clinical Capabilities, Accelerating Product Pipeline Development and Commercialization Opportunities AUSTIN, TX / ACCESSWIRE / May 13, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram"... ► Artikel lesen | |
01.05. | MONOGRAM ORTHOPAEDICS INC: Monogram Provides Regulatory Update Following Meeting with FDA | 448 | ACCESSWIRE | 510(k) Submission with FDA Accelerated for Early Second Half of 2024 AUSTIN, TX / ACCESSWIRE / May 1, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EMEIS | 7,565 | -0,33 % | Jean-Marc Boursier Appointed emeis' Chief Financial Officer | Regulatory News:
emeis (Paris:EMEIS):
Effective 2 September, Jean-Marc Boursier joins Laurent Guillot and his management team as Group Chief Financial Officer (CFO). Jean-Marc will take over... ► Artikel lesen | |
NANO-X IMAGING | 5,885 | -1,59 % | Nano-X Imaging Ltd. (NNOX): An Under The Radar AI Stock You Should Pay Attention To | ||
BUTTERFLY NETWORK | 1,615 | -3,29 % | Butterfly Network Inc.: Butterfly Network bringt seine nächste Generation Butterfly iQ3 in Europa auf den Markt | Butterfly iQ3 basiert auf der Ultrasound-on-Chip-Technologie der nächsten Generation, die sich durch eine einzigartige Bildqualität, neue 3D-Bildgebungsfunktionen und ein kompakteres und leichteres... ► Artikel lesen | |
GOODRX | 7,710 | -3,50 % | Spectrum Equity sells shares in GoodRx Holdings worth over $83k | ||
CARMAT | 2,400 | +0,42 % | CARMAT Publishes Its 2024 Half-Year Results and Provides an Update on Its Outlook | Half-year sales of €3.3 million, exceeding 2023 full-year sales
20 implants of the Aeson® artificial heart performed in the first half of 2024
17% cash-burn1 reduction compared to... ► Artikel lesen | |
JOINT CORP | 10,870 | -1,63 % | The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results | - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March... ► Artikel lesen | |
HYPERFINE | 0,900 | -2,17 % | Hyperfine, Inc.: Hyperfine Expands European Market Reach with Additional Strategic Distributor Partners | New distribution partnerships further global expansion plans for the Swoop system, growing the reach of Hyperfine to a total of twelve European countries
Hyperfine (Nasdaq: HYPR), the groundbreaking... ► Artikel lesen | |
MIMEDX | 6,150 | -3,60 % | MiMedx Group, Inc: MIMEDX Announces Second Quarter 2024 Operating and Financial Results | Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA... ► Artikel lesen | |
PROGYNY | 23,180 | -2,15 % | Here's What Affected Progyny's (PGNY) Share Price in Q2 | ||
PROCEPT BIOROBOTICS | 76,58 | +0,30 % | Procept Biorobotics director Rohit Desai sells over $7.7 million in company stock | ||
BIOMERICA | 0,355 | -7,29 % | Saudi Arabia approves Biomerica's prostate cancer test | ||
ATRICURE | 26,260 | +0,46 % | AtriCure, Inc.: AtriCure erhält eine erweiterte CE-Kennzeichnung für AtriClip-Geräte zur Reduzierung von Schlaganfällen bei Patienten mit Vorhofflimmern | Erweiterte Indikation auf Basis von zahlreichen klinischen Nachweisen für AtriClip-Geräte AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator im Bereich chirurgischer Behandlungen und Therapien... ► Artikel lesen | |
PROPHASE LABS | 2,200 | -2,65 % | ProPhase Labs, Inc.: ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated | Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database... ► Artikel lesen | |
OUTSET MEDICAL | 0,491 | -5,36 % | Outset Medical stock plunges to 52-week low of $0.5 | ||
TALKSPACE | 1,795 | -4,52 % | Talkspace Announces Second Quarter 2024 Results | 2Q 2024 Total revenue grew 29% year-over-year, driven by 62%year-over-year growth in Payor revenue Reduced GAAP Net loss to $0.5 million from $4.7 million year-over-year 2Q 2024 Adjusted EBITDA1 of... ► Artikel lesen |